Evidence map›Paper›PMID 42265434›Full record

ArticleEsophagus : official journal of the Japan Esophageal Society2026

FOLFOX plus nivolumab combination therapy for cisplatin-unfit patients with untreated advanced esophageal squamous cell carcinoma.

Nozomu Ogura, Shun Yamamoto, Ryuichi Morita, Hiroshi Imazeki, Hideaki Takahashi, Yoshitaka Honma, Tairo Kashihara, Daisuke Kurita, Koshiro Ishiyama, Hiroyuki Daiko and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nozomu OguraDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.
Shun YamamotoDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.
Ryuichi MoritaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.
Hiroshi ImazekiDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.
Hideaki TakahashiDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.
Yoshitaka HonmaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.
Tairo KashiharaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Daisuke KuritaDepartment of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Koshiro IshiyamaDepartment of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Hiroyuki DaikoDepartment of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Yasuyuki SetoDepartment of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Ken KatoDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan. kenkato@ncc.go.jp.ORCID http://orcid.org/0000-0002-1733-5072

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCombination chemotherapy with cisplatin and fluorouracil plus an immune checkpoint inhibitor (ICI) is a standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). However, cisplatin is unsuitable for patients with renal or cardiac dysfunction and older patients because of nephrotoxicity and the need for hydration. Oxaliplatin-based regimens (e.g., FOLFOX) have demonstrated clinically meaningful efficacy and are well tolerated in cisplatin-unfit patients with untreated advanced ESCC. This study investigated the effectiveness and safety of FOLFOX combined with an ICI in these patients.

methodsCisplatin-unfit patients with untreated advanced ESCC who received FOLFOX plus nivolumab at our institution between January 2024 and July 2025 were retrospectively identified. Progression-free survival, overall survival, and the response rate were evaluated as efficacy endpoints and adverse events as safety endpoints.

resultsSeventeen patients with a median age of 75 years (range, 62-82) were included. ECOG performance status was 0 in 3 cases (17.6%), 1 in 11 (64.7%), and 2 in 3 (17.6%). The main reasons for cisplatin ineligibility were older age (88.2%) and poor condition (58.8%). The response rate was 57.1% in patients with measurable lesions during a median follow-up of 9.9 months. Median progression-free survival was 6.5 months (95% confidence interval 3.6-not reached [NR]) and median overall survival was 15.6 months (4.5-NR). Common adverse events were neutropenia (41.2%) and leukopenia (35.3%). No treatment-related deaths occurred.

conclusionsFOLFOX plus nivolumab might have effectiveness and safety comparable with that of cisplatin and fluorouracil plus nivolumab in cisplatin-unfit patients with untreated advanced ESCC.

Indexed as

Advanced esophageal squamous cell carcinomaCisplatin-unfitFOLFOXNivolumab

Identifiers

PMID42265434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.